Xeris Biopharma (NASDAQ:XERS) Posts Earnings Results

Key Points

• Q1 revenue beat expectations as net product revenue rose 43% to $82.5M (total revenue $83.1M), and management raised full‑year revenue guidance to $380M–$390M.
• RECORLEV nearly doubled to $49.8M on record referrals and a commercial expansion (≈80 reps, ~12,000 targets) with incremental benefit expected in H2, while flagship Gvoke was flat at $20.8M and underperformed due to Medicare plan resets increasing patient out‑of‑pocket costs.
• The pipeline candidate XP‑8121 is on track to start Phase III later this year as R&D spend increases, and the company reported improved margins and reiterated a goal of positive adjusted EBITDA by 2026.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.01 EPS for the quarter, FiscalAI reports. The business had revenue of $83.13 million for the quarter, compared to analysts' expectations of $79.83 million. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%.

Here are the key takeaways from Xeris Biopharma's conference call:

• Q1 net product revenue rose 43% to $82.5M (total revenue $83.1M) and management raised FY revenue guidance to $380M–$390M, lifting the low end of prior guidance.
• RECORLEV nearly doubled to $49.8M on record referrals and new patient starts, and the company completed its commercial expansion (≈80 reps, targets increased to ~12,000), with incremental impact expected in H2.
• Gvoke was flat at $20.8M and underperformed internal expectations due to Medicare policy/plan resets that raised out‑of‑pocket costs and reduced prescription fills; management expects a recovery later in the year.
• The pipeline candidate XP‑8121 is on track to start Phase III later this year, leveraging the company’s XeriSol and device capabilities, with R&D spend planned to increase to support the program.
• Profitability metrics improved—gross margin 87% (+2%), adjusted EBITDA $15.1M, and net income $2.2M—with management reiterating a commitment to positive adjusted EBITDA for 2026 despite higher SG&A and R&D investments.

Xeris Biopharma Stock Performance

XERS traded up $0.26 during trading hours on Thursday, reaching $6.63. The company's stock had a trading volume of 5,563,284 shares, compared to its average volume of 1,314,657. Xeris Biopharma has a 52 week low of $4.30 and a 52 week high of $10.08. The company's 50-day moving average is $5.92 and its 200-day moving average is $6.96. The company has a debt-to-equity ratio of 16.10, a quick ratio of 1.57 and a current ratio of 2.19. The firm has a market cap of $1.14 billion, a PE ratio of -662.34 and a beta of 0.85.

Wall Street Analyst Weigh In

Several analysts have issued reports on XERS shares. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Xeris Biopharma in a research note on Monday, March 2nd. Wall Street Zen raised shares of Xeris Biopharma from a "buy" rating to a "strong-buy" rating in a research report on Saturday, March 7th. Finally, Weiss Ratings upgraded shares of Xeris Biopharma from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Wednesday, March 4th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $10.80.

Insiders Place Their Bets

In related news, insider Beth Hecht sold 16,667 shares of the company's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $6.25, for a total value of $104,168.75. Following the transaction, the insider owned 1,226,507 shares in the company, valued at approximately $7,665,668.75. This represents a 1.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James Aloysius Brady sold 10,834 shares of the stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $5.54, for a total transaction of $60,020.36. Following the completion of the transaction, the director directly owned 89,166 shares in the company, valued at approximately $493,979.64. This represents a 10.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 60,835 shares of company stock valued at $367,860. Company insiders own 6.47% of the company's stock.

Institutional Investors Weigh In On Xeris Biopharma

A number of institutional investors have recently made changes to their positions in XERS. Kestra Advisory Services LLC bought a new position in shares of Xeris Biopharma during the fourth quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd boosted its stake in Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company's stock valued at $59,000 after purchasing an additional 7,421 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company's stock valued at $63,000 after buying an additional 5,000 shares in the last quarter. Truvestments Capital LLC grew its holdings in Xeris Biopharma by 96.1% in the 4th quarter. Truvestments Capital LLC now owns 8,118 shares of the company's stock valued at $64,000 after buying an additional 3,979 shares in the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in Xeris Biopharma during the 4th quarter worth $67,000. Institutional investors own 42.75% of the company's stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.